Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant …
RESEARCH TRIANGLE PARK, N.C. , March 9 — Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell …
[Read the full article here]Related News:
Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV
StemCells, Inc. Initiates World’s First Neural Stem Cell Trial in Spinal Cord Injury